German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions
Journal of Neurology · 2024-11 · 271 (11) · 7330-7357
DOI: 10.1007/s00415-024-12503-0 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Neurology, online erschienen am 09.08.2024. Verfasst von Elke Kalbe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Mood Disorders, Neurology, Parkinson Disease. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.
Abstract (Originalsprache)
Background and objective Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson’s disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on “Parkinson’s disease” from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.
Methods
The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.
Results
Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson’s disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety.
Conclusions
In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.…
- Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Neurology, School of Medicine and Health Science, Carl Von Ossietzky University of Oldenburg, Oldenburg, Germany.
- Research Center of Neurosensory Science, Carl Von Ossietzky University of Oldenburg, Oldenburg, Germany.
- Department of Neurology, Evangelical Hospital, Oldenburg, Germany.
- Department of Neurology, University Clinic Eppendorf, Hamburg, Germany.
Förderung
- Universitätsklinikum Köln
Zitieren
APA
Kalbe, E., Folkerts, A. K., Witt, K., Buhmann, C., Liepelt-Scarfone, I., & German Parkinson’s Guidelines Group (2024). German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions. Journal of Neurology, 271(11), 7330-7357. https://doi.org/10.1007/s00415-024-12503-0
Vancouver
Kalbe E, Folkerts AK, Witt K, Buhmann C, Liepelt-Scarfone I, German Parkinson’s Guidelines Group. German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions. Journal of Neurology. 2024;271(11):7330-7357. doi:10.1007/s00415-024-12503-0
BibTeX
@article{Kalbe2024,
author = {Kalbe, Elke and Folkerts, Ann-Kristin and Witt, Karsten and Buhmann, Carsten and Liepelt-Scarfone, Inga and German Parkinson’s Guidelines Group, German Parkinson’s Guidelines Group},
title = {German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions},
journal = {Journal of Neurology},
year = {2024},
volume = {271},
number = {11},
pages = {7330--7357},
doi = {10.1007/s00415-024-12503-0}
}
EUVIMED